RUNX1 and cancer: It is consistent to another study where the cancer‐free mice were received a much higher dose (300 mg kg−1/d) for a month.[35] Although Runx1 is suggested to be an important regulator for hematopoiesis, a new study demonstrated that its hematopoietic function can be replaced by other Runx1‐independent mechanisms (e.g., GATA2) in the Runx1‐KO hematopoietic stem cells.[41] In addition, our in vitro experiments further demonstrated that Runx1 inhibition can effectively block MMT without cytotoxicity on the primary macrophages.